Current Report Filing (8-k)
June 15 2017 - 4:44PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): June 14, 2017
ZIOPHARM Oncology, Inc.
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
Delaware
|
|
001-33038
|
|
84-1475642
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
One First Avenue, Parris Building 34, Navy Yard Plaza
Boston, Massachusetts
|
|
02129
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
(617)
259-1970
(Registrants telephone number, including area code)
Not applicable
(Former
Name or Former Address, if Changed Since Last Report)
Check the appropriate box below
if the
Form 8-K
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
|
☐
|
Soliciting material pursuant to
Rule 14a-12
under the Exchange Act
(17 CFR 240.14a-12).
|
☐
|
Pre-commencement
communications pursuant to
Rule 14d-2(b) under
the Exchange Act (17 CFR
240.14d-2(b)).
|
☐
|
Pre-commencement
communications pursuant to
Rule 13e-4(c) under
the Exchange Act (17 CFR
240.13e-4(c)).
|
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act (17 CFR 230.405) or Rule
12b-2
of the Exchange Act (17 CFR
240.12b-2).
Emerging growth company ☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 5.07
|
Submission of Matters to a Vote of Security Holders.
|
ZIOPHARM Oncology, Inc., or the
Company, held its 2017 annual meeting of stockholders on June 14, 2017, at which all proposals properly brought before the meeting and requiring approval were approved by the requisite vote. The final results of the voting with respect to each
proposal are set forth below.
(1) The stockholders elected six directors to serve as members of the Companys board of directors
until the next annual meeting of the stockholders. The stockholders present in person or by proxy cast the following numbers of votes in connection with the election of directors, resulting in the election of all proposed director nominees:
|
|
|
|
|
|
|
|
|
|
|
|
|
Nominee
|
|
For
|
|
|
Withheld
|
|
|
Broker Non-Votes
|
|
Sir Murray Brennan, M.D., GNZM
|
|
|
40,989,025
|
|
|
|
8,521,383
|
|
|
|
63,470,475
|
|
James A. Cannon
|
|
|
42,760,768
|
|
|
|
6,749,640
|
|
|
|
63,470,475
|
|
Senator Wyche Fowler, Jr.
|
|
|
42,701,365
|
|
|
|
6,809,043
|
|
|
|
63,470,475
|
|
Randal J. Kirk
|
|
|
47,437,743
|
|
|
|
2,072,665
|
|
|
|
63,470,475
|
|
Scott Tarriff
|
|
|
42,171,079
|
|
|
|
7,339,329
|
|
|
|
63,470,475
|
|
Michael Weiser, M.D., Ph.D.
|
|
|
39,398,527
|
|
|
|
10,111,881
|
|
|
|
63,470,475
|
|
There were no abstentions with respect to Proposal 1.
(2) The stockholders ratified the appointment of RSM US LLP as the independent registered public accounting firm of the Company for
2017. There were 110,874,351 votes cast for the proposal; 1,151,293 votes were cast against the proposal; 955,239 votes abstained; and there were no broker
non-votes.
(3) The stockholders approved, on a
non-binding
advisory basis, the compensation of the Companys
named executive officers, as disclosed in the Companys proxy statement for the 2017 annual meeting. There were 42,010,077 votes cast for the proposal; 6,492,872 votes were cast against the proposal; 1,007,459 votes abstained; and there were
63,470,475 broker
non-votes.
(4) The stockholders recommended, on a
non-binding
advisory basis, the preferred frequency for the solicitation of future advisory stockholder approval of the compensation of the Companys named executive officers be held every year, based on the
following votes. There were 47,607,659 votes cast for one year; 414,354 votes cast for two years; 1,221,542 votes cast for three years; and 266,853 votes abstained.
Consistent with the stockholder voting results above and the recommendation of the board of directors of the Company as disclosed in the
Companys proxy statement for the 2017 annual meeting, the board of directors of the Company has determined to solicit a
non-binding
advisory vote on the compensation of the Companys named
executive officers every year until the next required stockholder vote on the frequency of such
non-binding
advisory vote, or until the board of directors of the Company determines that a different
frequency of such
non-binding
advisory vote is in the best interest of the Companys stockholders.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
ZIOPHARM Oncology, Inc.
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Kevin G. Lafond
|
Date: June 15, 2017
|
|
|
|
|
|
Name:
|
|
Kevin G. Lafond
|
|
|
|
|
|
|
Title:
|
|
Vice President, Chief Accounting Officer and Treasurer
|
ZIOPHARM Oncology (NASDAQ:ZIOP)
Historical Stock Chart
From Mar 2024 to Apr 2024
ZIOPHARM Oncology (NASDAQ:ZIOP)
Historical Stock Chart
From Apr 2023 to Apr 2024